Beijing Innocare Pharma Tech Co. Ltd. has divulged heterocyclic compounds acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for treatment of cancer.
Tuojie Biotech (Shanghai) Co. Ltd. has identified mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer, inflammation and autoimmune diseases.
National Institute of Pharmaceutical R&D Co. Ltd. has synthesized high affinity nerve growth factor receptor (NTRK1; TRKA) and its mutant inhibitors reported to be useful for the treatment of cancer.
Ajinomoto Co. Inc.'s Ajinomoto Bio-Pharma Services has announced a license agreement with Exelixis Inc. to incorporate AJICAP, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs for cancer.
A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Since the advent of COVID-19 mRNA vaccines, the space has steadily grown hotter, a situation on which Anima Biotech Inc. has capitalized by way of a potential $580 million-plus deal with Abbvie Inc. to deploy mRNA biology modulators for three targets across oncology and Immunology.
RSS
